Document Detail


Neurotensin pulmonary metabolism in normal and asthmatic subjects.
MedLine Citation:
PMID:  14650643     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The role of pulmonary metabolism of endogenous neurotensin (NT) in asthma is still unclear. Information on this subject in humans is scarce. OBJECTIVES: Evaluation of the pulmonary metabolism of the endogenous NT in asthmatic subjects during symptom-free periods and after a methacoline challenge test and in healthy individuals. METHODS: Ten asthmatic subjects (aged 34 to 70 years), diagnosed with extrinsic (n = 5), atopic (n = 3), and mixed asthma (n = 2), were compared to a group of 10 healthy individuals (aged 45 to 69 years). The asthmatic group of patients was evaluated with a PD20-FEV1 methacoline challenge test 3 days after a washout period from cessation of their regular medications. Two catheters were inserted in order to draw blood samples for the evaluation of NT concentration: one was inserted into the pulmonary artery and the other into the radial artery. The mean concentration of NT in pulmonary and systemic arterial blood, as well as the arteriovenous difference of NT and the absolute value of production rate [PR/m'], PR/m'/kg and PR/m'/m2 were calculated for each participant. RESULTS: The mean neurotensin concentration in normal subjects was higher in mixed venous blood (pulmonary artery) than in systemic arterial blood (p < 0001). Similarly, mean NT mixed venous levels in asthmatic subjects was shown to be higher than mean NT levels in systemic arterial blood, before and after the bronchoconstriction with methacoline (p = 0.05 and p = 0.02, respectively). In contrast, the arterovenous difference and the mean values of PR of NT were similar in both groups. CONCLUSIONS: Our findings suggest that (1) NT concentration in mixed venous blood changes in transit through the pulmonary parenchyma, indicating that the pulmonary parenchyma is an important site of NT metabolism; (2) Pulmonary clearance of NT is unaffected by cholinergic bronchoconstriction. Further clinical studies are needed in order to improve both the understanding and the therapeutic approach of the neurogenic process in asthmatic subjects.
Authors:
P Vacca; R Carbone; A Monselise; M Grosso; G Bottino
Related Documents :
637273 - Hazards of central venous pressure monitoring.
11726423 - Thoracic, but not lumbar, epidural anesthesia improves cardiopulmonary function in ovin...
2895903 - Microvascular anatomy of heubner's recurrent artery.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  European review for medical and pharmacological sciences     Volume:  7     ISSN:  1128-3602     ISO Abbreviation:  Eur Rev Med Pharmacol Sci     Publication Date:    2003 May-Jun
Date Detail:
Created Date:  2003-12-02     Completed Date:  2004-01-05     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9717360     Medline TA:  Eur Rev Med Pharmacol Sci     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  75-80     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Genoa University, Genoa, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Asthma / chemically induced*,  metabolism*
Humans
Lung / metabolism*
Male
Methacholine Chloride / administration & dosage,  adverse effects*
Middle Aged
Neurotensin / metabolism*
Chemical
Reg. No./Substance:
39379-15-2/Neurotensin; 62-51-1/Methacholine Chloride

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Thrombus formation in the left atrial appendage in the course of atrial fibrillation.
Next Document:  Hyperhomocysteinemia in preeclampsia is associated to higher risk pressure profiles.